ClinicalTrials.gg
CompletedNCT04881825EASE SBS 3Updated Sep 8, 2026

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

A Phase 3 interventional study of Glepaglutide in Short Bowel Syndrome, sponsored by Zealand Pharma. Completed at 19 sites in 8 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Short Bowel Syndrome with a site in Germany — 4 open to participants now, 6 under way, 4 of them phase 3. Short Bowel Syndrome · Germany.

Enrollment
9th of 15
84 · median 86
Started
2021
with 2 others
Phase 3
12 of 17
2 open now
Registered
12th of 17
by date
Lead sponsor
5 of 17
Zealand Pharma

Among the 17 studies in Short Bowel Syndrome with a site in Germany, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2021, is one of 12 in phase 3, and was the 12th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

4 of the 17 studies in Short Bowel Syndrome with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Short Bowel Syndrome with a site in Germany, or all of them as a file.
02

Study summary

This trial is an extension trial to EASE SBS 2. The study looks at whether glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment. Participants in this trial will receive glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.) for approximately 2 years.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activity
  • Completed the full treatment period of the extension trial EASE SBS 2 (ZP1848-17127)

Exclusion criteria

Exclusion Criteria:

  • Any condition, disease, or circumstance that in the Investigator's opinion would put the patient at any undue risk, prevent completion of the trial, or confound the planned assessments of the trial
  • Not having a colonoscopy performed at End of Trial in EASE SBS 2 (for patients with remnant colon). Note. The results of the colonoscopy must not give rise to any safety concerns. A colonoscopy performed within 6 months prior to End of Trial and not giving rise to any safety concerns is accepted. For patients with a remnant colon, which is not connected to the passage of foods and is thereby dormant, a computerized tomography (CT) scan or magnetic resonance imaging (MRI) will suffice at the discretion of the Investigator
  • Use of GLP-1, GLP-2, human growth hormone (HGH), dipeptidyl peptidase-4 (DPP-4) inhibitors, somatostatin, or analogs thereof within 3 months. Note: Prior use of glepaglutide trial drug is allowed
  • Females of , who are pregnant, breast-feeding, intend to become pregnant, or are not using highly effective methods
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    once-weekly glepaglutide

    All participants will receive 10 mg of glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.)

    Drug: Glepaglutide

Interventions

  • Glepaglutide will be delivered in a single-use autoinjector.

    Also known as: ZP1848

06

What researchers measure

Primary outcomes

  1. Incidence and type of Adverse Events (AEs)

    For AEs with onset or worsening following Visit 1

    Time frame: After 108 weeks

Secondary outcomes

  1. Incidence and type of Serious Adverse Events (SAEs)

    For AEs with onset or worsening following Visit 1

    Time frame: After 108 weeks

  2. Incidence and type of Adverse Events of Special Interest (AESIs)

    For AEs with onset or worsening following Visit 1

    Time frame: After 108 weeks

  3. Change in body temperature

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  4. Change in heart rate

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  5. Change in blood pressure

    Seated diastolic and systolic blood pressure

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  6. Change in body weight

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  7. Number of participants with clinically significant changes in 12-Lead electrocardiogram (ECG)

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  8. Change in hematology - hemoglobin

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  9. Change in hematology - hematocrit

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  10. Change in hematology - white blood cell count

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  11. Change in hematology - platelet count

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  12. Change in biochemistry - sodium

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  13. Change in biochemistry - potassium

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  14. Change in biochemistry - chloride

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  15. Change in biochemistry - bicarbonate

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  16. Change in biochemistry - blood urea nitrogen

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  17. Change in biochemistry - creatinine

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  18. Change in biochemistry - creatinine clearance

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  19. Change in biochemistry - glucose

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  20. Change in biochemistry - calcium

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  21. Change in biochemistry - phosphorous

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  22. Change in biochemistry - alkaline phosphatase

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  23. Change in biochemistry - alanine aminotransferase (ALT)

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  24. Change in biochemistry - aspartate aminotransferase (AST)

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  25. Change in biochemistry - International Normalized Ratio (INR)

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  26. Change in biochemistry - gamma-glutamyl transferase (GGT)

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  27. Change in biochemistry - lactic dehydrogenase

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  28. Change in biochemistry - conjugated bilirubin

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  29. Change in biochemistry - total bilirubin

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  30. Change in biochemistry - total protein

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  31. Change in biochemistry - albumin

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  32. Change in biochemistry - amylase

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  33. Change in biochemistry - uric acid

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  34. Change in biochemistry - C-reactive protein

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  35. Change in urinalysis - blood

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  36. Change in urinalysis - glucose

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  37. Change in urinalysis - leukocytes

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  38. Change in urinalysis - pH

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  39. Change in urinalysis - osmolality

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  40. Change in urinalysis - protein

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  41. Change in urinalysis - sodium

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  42. Change in urinalysis - potassium

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  43. Anti-glepaglutide antibodies

    Time frame: Week 0, Week 108

  44. Antibody reactivity to ZP1848

    Time frame: Week 0, Week 108

  45. Cross-reactivity to glucagon-like peptide-2 (GLP-2)

    Time frame: Week 0, Week 108

  46. Glepaglutide neutralizing antibodies

    Time frame: Week 0, Week 108

  47. Reduction in weekly Parenteral Support (PS) volume

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  48. Reduction of at least 20 percent in weekly PS volume

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  49. Reduction in days on PS greater than or equal to 1 day per week

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

  50. Reduction in weekly PS volume of 100 percent (weaned off)

    Time frame: Week 0 in lead-in trial (EASE SBS 1), Week 108

07

Study locations

19 sites
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • Mayo Clinic College of Medicin
    Rochester, Minnesota 55905, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Vanderbilt University Medical Center, Nashville
    Nashville, Tennessee 68198-3285, United States
  • Universitair Ziekenhuis Leuven
    Leuven, Belgium
  • Rigshospitalet
    Copenhagen, Denmark
  • Hôpital Beaujon
    Clichy, France
  • Centre Hospitalier Lyon-Sud
    Pierre-Bénite, France
  • Charité - Universitätsmedizin Berlin
    Berlin, Germany
  • Universitätsklinikum Bonn
    Bonn, 53127, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt, Germany
  • Asklepios Kliniken Hamburg GmbH
    Hamburg, Germany
  • Universitätsmedizin Rostock
    Rostock, Germany
  • UMC Radboud Nijmegen
    Nijmegen, Netherlands
  • Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi
    Lodz, Poland
  • Szpital Skawina sp. z o.o. im. Stanley Dudricka
    Skawina, Poland
  • St Mark's Hospital
    Harrow, United Kingdom
  • UCLH Foundation NHS Trust
    London, United Kingdom
  • Norfolk and Norwich University Hospitals
    Norwich, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Apr 2026, 58 months.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 58 months is above that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2021
First posted
May 11, 2021
StartActual
Jun 16, 2021
Primary completionActual
Apr 30, 2026
CompletionActual
Apr 30, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04881825
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
May 11, 2021
Start date
Jun 16, 2021
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Sep 8, 2026

Study contacts

Zealand Pharma
study director · Zealand Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glepaglutide

Start the discussion